Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer.

Pinto-Leite R, Arantes-Rodrigues R, Palmeira C, Colaço B, Lopes C, Colaço A, Costa C, da Silva VM, Oliveira P, Santos L.

Biomed Pharmacother. 2013 Mar;67(2):116-21. doi: 10.1016/j.biopha.2012.11.007. Epub 2012 Dec 26.

PMID:
23433853
2.

The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.

Ma BB, Lui VW, Hui EP, Lau CP, Ho K, Ng MH, Cheng SH, Tsao SW, Chan AT.

Invest New Drugs. 2010 Aug;28(4):413-20. doi: 10.1007/s10637-009-9269-x. Epub 2009 May 27.

PMID:
19471857
3.

In vivo and in vitro effects of RAD001 on bladder cancer.

Vasconcelos-Nóbrega C, Pinto-Leite R, Arantes-Rodrigues R, Ferreira R, Brochado P, Cardoso ML, Palmeira C, Salvador A, Guedes-Teixeira CI, Colaço A, Palomino LF, Lopes C, Santos L, Oliveira PA.

Urol Oncol. 2013 Oct;31(7):1212-21. doi: 10.1016/j.urolonc.2011.11.002. Epub 2011 Dec 9.

PMID:
22169072
4.

Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.

Treeck O, Wackwitz B, Haus U, Ortmann O.

Gynecol Oncol. 2006 Aug;102(2):292-9. Epub 2006 Jan 26.

PMID:
16443261
5.

Apoptosis of bladder cancer by sodium butyrate and cisplatin.

Maruyama T, Yamamoto S, Qiu J, Ueda Y, Suzuki T, Nojima M, Shima H.

J Infect Chemother. 2012 Jun;18(3):288-95. doi: 10.1007/s10156-011-0322-2. Epub 2011 Oct 26.

PMID:
22041988
6.

Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer.

Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, Kassouf W.

Cancer Biol Ther. 2009 Dec;8(24):2339-47. Epub 2009 Dec 2.

PMID:
20061787
7.
8.
9.

Emetine dihydrochloride: a novel therapy for bladder cancer.

Foreman KE, Jesse JN 3rd, Kuo PC, Gupta GN.

J Urol. 2014 Feb;191(2):502-9. doi: 10.1016/j.juro.2013.09.014. Epub 2013 Sep 14.

PMID:
24045224
10.

The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.

Makhlin I, Zhang J, Long CJ, Devarajan K, Zhou Y, Klein-Szanto AJ, Huang M, Chernoff J, Boorjian SA.

BJU Int. 2011 Jul;108(2 Pt 2):E84-90. doi: 10.1111/j.1464-410X.2010.09844.x. Epub 2010 Nov 2.

11.

Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species.

Matsui Y, Ueda S, Watanabe J, Kuwabara I, Ogawa O, Nishiyama H.

Cancer Res. 2007 Feb 1;67(3):1212-20.

12.
13.

MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway.

Sun D, Sawada A, Nakashima M, Kobayashi T, Ogawa O, Matsui Y.

Urol Oncol. 2015 Mar;33(3):111.e17-26. doi: 10.1016/j.urolonc.2014.10.018. Epub 2014 Dec 9.

14.

Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines.

Pinto-Leite R, Arantes-Rodrigues R, Ferreira R, Palmeira C, Colaço A, Moreira da Silva V, Oliveira P, Lara Santos L.

Urol Oncol. 2014 Jan;32(1):41.e11-22. doi: 10.1016/j.urolonc.2013.04.012. Epub 2013 Sep 10.

PMID:
24035472
15.

Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.

Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, Zhang YF, Xie Z, Wu YL.

Cancer Chemother Pharmacol. 2012 Nov;70(5):707-16. doi: 10.1007/s00280-012-1946-3. Epub 2012 Sep 2.

PMID:
22941374
16.
17.

Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.

O'Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, Lane HA.

Anticancer Drugs. 2011 Jan;22(1):58-78. doi: 10.1097/CAD.0b013e3283400a20.

PMID:
20890178
18.

Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells.

Ong PS, Wang XQ, Lin HS, Chan SY, Ho PC.

Int J Oncol. 2012 May;40(5):1705-13. doi: 10.3892/ijo.2012.1354. Epub 2012 Feb 2.

PMID:
22328352
19.

Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil.

Mizutani Y, Wu XX, Yoshida O, Shirasaka T, Bonavida B.

Oncol Rep. 1999 Sep-Oct;6(5):979-82.

PMID:
10425290
20.

The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.

Dragowska WH, Weppler SA, Qadir MA, Wong LY, Franssen Y, Baker JH, Kapanen AI, Kierkels GJ, Masin D, Minchinton AI, Gelmon KA, Bally MB.

BMC Cancer. 2011 Oct 1;11:420. doi: 10.1186/1471-2407-11-420.

Supplemental Content

Support Center